Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

NCT03648814 | Recruiting DMC

• 1 other identifier: REC6100321
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Conditions

Glaucoma, Neovascular; Vascular Endothelial Growth Factor Overexpression

Keywords

Neovascular glaucoma

Outcome Measures

Primary Outcomes (1)

• regression of nevolascularization

  Amount of nevolascular of iris and angle regression

  2 months

Secondary Outcomes (2)

• IOP reduction

  2 months

• Injection complication

  2 days

Study Arms (2)

Intracameral injection

EXPERIMENTAL

Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection

Procedure: Intracameral injection

Intravitreal injection

EXPERIMENTAL

Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection

Procedure: Intravitreal injection

Interventions

Intracameral injection PROCEDURE

A/C injection of 1.25 mg/0.05 mL bevacizumab

Intracameral injection

Intravitreal injection PROCEDURE

Vitreous injection of 1.25 mg/0.05 mL bevacizumab

Intravitreal injection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of neovascular glaucoma
• The patients having IOP \> 21 mmHg, having the indication for trabeculectomy
• The patients' age of at least 18-year-old
• The patients having visual potential at least hand motion.
• Present of NVI or NVA.
• Willing and able to provide informed consent to participate in the study
• Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

You may not qualify if:

• One eye patient
• Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
• Cannot obtain endothelial cell count.
• History of bevacizumab or fluorescence dye allergy.
• Active infectious ocular disease including endophthalmitis and corneal ulcer
• History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
• Has or planning to be pregnant or breastfeeding

Sponsors & Collaborators

• Prince of Songkla University: lead

Study Sites (1)

Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University

Hat Yai, Changwat Songkhla, 90110, Thailand

RECRUITING

MeSH Terms

Conditions

Glaucoma, Neovascular

Interventions

Intracameral Injection; Intravitreal Injections

Condition Hierarchy (Ancestors)

Glaucoma; Ocular Hypertension; Eye Diseases

Intervention Hierarchy (Ancestors)

Injections, Intraocular; Injections; Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Assoc.Prof.Weerawat Kiddee, MD

  Prince of Songkla University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Assoc.Prof.Weerawat Kiddee, MD

CONTACT

+66874954626; kweerawat@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof.

Study Record Dates

• First Submitted: August 24, 2018
• First Posted: August 27, 2018
• Study Start: August 1, 2018
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: August 21, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

TH (1)